



High-dose therapy followed by autologous bone mar-
row transplantation has been used for recurrent and high-
risk non-Hodgkin’s lymphoma (NHL) with favorable results
[1-10]. Recently, a randomized trial demonstrated the supe-
riority of autotransplantation for patients with recurrent
intermediate-grade NHL over standard salvage chemo-
therapy [11]. Peripheral blood progenitor cells (PBPCs)
have been increasingly used instead of autologous bone
marrow, with faster engraftment times reported [12-14],
although 1 study demonstrated similar engraftment of gran-
ulocyte colony-stimulating factor (G-CSF)–stimulated bone
marrow compared with G-CSF–mobilized PBPCs. The
major cause for transplantation failure remains relapse after
autografting, and it is not clear what role tumor contamina-
tion of the autograft plays [15,16].
Purging techniques using chemotherapeutic agents or
monoclonal antibodies have been described [17,18], and 1
report suggests that cytotoxic purging of autologous marrow
may prevent relapse in acute myelogenous leukemia [19]. We
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ABSTRACT
Our purpose was to evaluate the outcome and costs of high-dose chemotherapy and autologous peripheral blood
progenitor cell (PBPC) transplantation in patients with the inability to mobilize sufficient numbers of PBPCs to
allow rapid engraftment after PBPC transplantation. We treated 172 consecutive non-Hodgkin’s lymphoma (NHL)
patients with cyclophosphamide and granulocyte colony-stimulating factor followed by apheresis to collect PBPCs.
The cells were separated on a Percoll gradient and purged with monoclonal antibodies and complement. The
patients were categorized as “good” mobilizers if a collection of ≥2  106 CD34+ cells/kg was obtained (n = 138, 80%)
or “poor” mobilizers if <2  106 CD34+ cells/kg were obtained (n = 34, 20%). With a median follow-up of 3.5 years,
there is no statistically significant difference in actuarial event-free survival, overall survival, or relapse for good mobi-
lizers compared with poor mobilizers. However, there was a trend toward increasing nonrelapse, transplantation-
related mortality of 11.8% for poor mobilizers versus 3.6% for good mobilizers (P = .08) and early death from all
causes including relapse within 120 days (poor 20.6% versus good 8.7%, P = .06). The total cost for bone marrow
transplantation–related care was significantly higher, at $140,264 for poor mobilizers versus $80,833 for good mobi-
lizers (P = .0001). The population of patients with NHL who mobilize PBPCs poorly into the circulation have a
higher cost for posttransplant support. However, there is no significant difference in relapse, event-free survival, or
overall survival for such patients compared with those who mobilize PBPCs easily.
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previously described a technique for enriching and purging
PBPCs using a discontinuous Percoll gradient followed by
treatment with monoclonal antibodies and complement [20].
Using this approach in an initial 21 patients, we determined
that the minimum number of CD34+ cells needed for rapid
engraftment of white blood cells and platelets was 2  106
CD34+ cells/kg, similar to estimates of cell requirements
reported by other groups [21-27].
In this report, we describe the outcome of 172 consecu-
tive patients with NHL who underwent purged autologous
transplantation and describe a group of patients who failed
to mobilize adequate numbers of PBPCs. The long-term
survival and costs of the transplantation procedure for the
patients who mobilized poorly are compared with patients
who had good mobilization of PBPCs.
MATERIALS AND METHODS
Patient Eligibility
Between June 1994 and July 1998, 172 consecutive
patients with relapsed, refractory, or poor-risk NHL were
treated with high-dose chemotherapy with or without radio-
therapy followed by autologous hematopoietic cell trans-
plantation. Patients were eligible if they had failed to
achieve a complete remission (CR) with standard chemo-
therapy (induction failure), if they were considered to be at
high risk for early relapse in ﬁrst CR [28], or if they relapsed
after attaining a CR. The majority of patients had interme-
diate- or high-grade histology as described in the National
Cancer Institute Working Formulation [29]. Patients with
low-grade histology were only eligible if their disease was
poorly controlled with or recurrent after standard therapies.
Patients received cytoreduction with conventional
chemotherapy in an attempt to achieve a minimal disease
state before transplantation. Previous treatment history and
histology of the disease determined the selection of conven-
tional cytoreduction. The number of chemotherapy cycles
given was determined by the response to the cytoreductive
regimen as assessed by physical examination and radiological
imaging studies [30]. All pathology specimens were
reviewed at Stanford University. The study protocols used
were approved by the Institutional Review Board at Stan-
ford University, and all patients in this study gave written
informed consent.
Study Definitions
Patients without clinical or radiological evidence of dis-
ease or bone marrow involvement with lymphoma were
deﬁned as being in CR, whereas patients with residual dis-
ease were defined as being in partial remission (PR) or as
having active disease. Patients who did not achieve a CR
with standard chemotherapy at initial presentation were
considered induction failures. Resistant disease was deﬁned
as no response or growth of lymphoma during standard
cytoreduction chemotherapy. Relapse was deﬁned as biopsy-
proven disease in a new site or growth of disease in any pre-
viously involved sites.
Transplantation-related mortality included death from
any cause except relapse occurring within 120 days after
transplantation. The number of cycles of chemotherapy was
calculated based on the number of individual complete
cycles of chemotherapy. A complete course of an intensive
chemotherapy regimen, such as VACOP-B (etoposide [VP-
16], doxorubicin, cyclophosphamide [CY], vincristine, pred-
nisone, bleomycin), was calculated as 6 cycles, comparable
to 6 cycles of CHOP (CY, doxorubicin, vincristine, pred-
nisone) chemotherapy. The day of autologous bone marrow
(ABM) transplantation or PBPC transplantation was deﬁned
as day 0 for all survival and relapse analyses. Patients were
categorized as “poor” mobilizers if <2  106 CD34+ cells/kg
were collected and as “good” mobilizers if ≥2  106 CD34+
cells/kg were collected. These deﬁnitions are based on our
previously reported data regarding the number of CD34+
cells infused and the engraftment data [20] as well as data
reported by other groups [26,27].
Patient Characteristics
Patient characteristics are described in Table 1. In this
study, 172 patients were treated using 2 preparatory regimens.
A total of 98 patients received a preparatory regimen of car-
mustine (BCNU), VP-16, and CY [30]; 74 patients were
treated with fractionated total body irradiation (fTBI), VP-16,
and CY [9]. Patients were treated with BCNU, VP-16, CY if
they had received prior radiotherapy to the chest or pelvis, if
posttransplant radiotherapy was planned for sites of bulky dis-
ease, or if the patient’s age or Karnofsky performance status
was believed to make fTBI too toxic. Beginning in June 1996,
all patients received the BCNU-containing regimen unless
they had low-grade NHL or mantle cell histology [30].
Collection and Purging of Hematopoietic Precursor
Cells
Collection of PBPCs was performed as previously
described [20]. Brieﬂy, patients were treated with 4 g/m2 CY
intravenously over 2 hours via a central venous catheter.
Twenty-four hours after completion of CY, patients received
G-CSF 10 µg/kg per day by subcutaneous injection. After
the white blood cell count increased to 1000/µL, apheresis
was started using a Cobe Spectra Cell Separator (Lakewood,
CO) at a rate of 80 mL/min for approximately 200 minutes.
Additional processing and purging was performed when the
CD34+ cell content was >100 CD34+ cells/µL and after >1 
106 CD34+ cells were collected during a single apheresis.
CD34 quantification was performed using apheresis prod-
ucts stained with monoclonal antibodies to CD34
(HPCA-2; Becton Dickinson, San Jose, CA) and analyzed
using a fluorescence-activated cell sorter [20]. Additional
apheresis collections were stored as back-up grafts. These
“back-up” cells were not routinely given to patients unless
engraftment failure occurred.
Percoll gradients were prepared using discontinuous gra-
dients of 2.5% steps from 40% to 50% stock solutions [20].
Cells from the low-density fractions (1-3) obtained from a
single apheresis procedure were collected, pooled, treated
with monoclonal antibodies and complement, and frozen in
dimethylsulfoxide and autologous serum. Beginning with the
54th patient treated on this protocol, cells were prepared by
single-step density gradient separation using BDS 60 tubes
(Activated Cell Therapy, Mountain View, CA). These 50-mL
tubes contain 15 mL of an isotonic solution of colloidal silica
with an adjusted density to enrich CD34+ cells during cen-
trifugation. These tubes are modiﬁed to facilitate enrichment
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of the CD34+ cell population from the interface by trapping
nonessential cells in the lower compartment of the centrifu-
gation tube. Purging with antibodies was performed as previ-
ously described [20]. Patients had bone marrow collected and
purged if they failed to obtain the goal of 2  106 CD34+
cells/kg. Good mobilizers were transplanted with purged
PBPCs. Poor mobilizers received purged bone marrow,
purged PBPCs, or purged bone marrow plus purged PBPCs
based on physician discretion.
Supportive Care and Follow-up
Patients received supportive care as previously described
[30]. G-CSF was administered at a dose of 5 µg/kg daily from
day 1 until the absolute neutrophil count exceeded 500/µL for
at least 3 consecutive days. Beginning in April 1997, G-CSF
administration began on day 6 [31]. Bone marrow biopsies
were obtained routinely to assess engraftment and examined
for lymphoma on days 60 and 180 and yearly thereafter.
Patients were subsequently examined by a physician every 2 to
6 months, with chest radiographs performed at each visit and
additional imaging studies obtained as clinically indicated.
Statistical Analysis
The last follow-up was completed on February 29, 2000,
and event-free survival and overall survival were calculated
from the day of ABM or PBPC infusion until the date of last
follow-up examination and calculated by the method of
Kaplan and Meier [32]. The relationships between clinical
parameters and survival were evaluated using the log-rank
test [33] for nominal data and proportional hazards for con-
tinuous variables. Multivariate analysis evaluating factors
associated with survival was performed using the propor-
tional hazards model of Cox [34] with forward stepwise
selection. Statistical analyses comparing the 2 groups of
patients used the rank sum test and 2 analysis, as indicated.
Multivariate analysis of factors associated with ability to
mobilize PBPCs was performed using logistic regression.
RESULTS
Mobilization of PBPCs
A total of 170 patients had adequate numbers of CD34+
cells to allow accurate analysis. Two patients who were poor
mobilizers had CD34+ counts of <0.1% in the apheresis prod-
uct, which was below the level of sensitivity of the method.
Good mobilizers had a median of 4.6  106 CD34+ cells/kg
(range 2.0  106 to 29.1  106), whereas poor mobilizers had
a median of 0.84  106 cells/kg (range 0  106 to 1.9  106)
(P < .0001). A median of 4 apheresis procedures were per-
formed for poor mobilizers, and a median of 2 apheresis pro-
cedures were performed for good mobilizers. A total of 34
patients (20%) were considered poor mobilizers and were
transplanted with PBPCs alone (n = 14), ABM alone (n = 15),
or ABM and PBPCs (n = 5).
We analyzed multiple factors in an attempt to predict
which patients would mobilize PBPCs poorly (Table 1).
Poor mobilizers received a higher median number of
chemotherapy cycles (9 cycles) than good mobilizers, who
had been treated with 8 cycles (P = .04); however, there was
a signiﬁcant degree of overlap of the ranges. Female patients
were less likely to mobilize well, with a median of 3.0  106
CD34+ cells/kg compared with 4.5  106 CD34+ cells/kg in
Table 1. Patient Characteristics Separated by Ability to Mobilize Peripheral Blood Progenitor Cells*
Patient Characteristic Poor Mobilizers† (n = 34) Good Mobilizers† (n = 138) P‡
No. of prior chemotherapy regimens, median (range) 2 (1-4) 2 (1-5) .10
Median age, y (range) 53 (30-64) 49 (14-70) .17
No. of prior chemotherapy cycles, median (range) 9 (3-24) 8 (1-22) .04
Status at transplantation, %
First CR/PR 3 14 —
Second CR/PR 62 50 .26
Third or subsequent CR/PR 14 8 —
Induction failure 21 28 —
Prior radiotherapy treatment, % 26 34 .52
Histological grade, %
High 0 3 —
Intermediate 83 83 .86
Low 17 14 —
Bone marrow involvement, %§ 23 24 .99
Sex, %
Female 65 36 <.01
Male 35 64 —
Preparatory regimen, %
fTBI/VP-16/CY 50 41 .44
BCNU/VP-16/CY 50 59 —
Chemoresistant disease, % 06 05 .50
*CR indicates complete remission; PR, partial remission; fTBI, fractionated total body irradiation; VP-16, etoposide; CY, cyclophosphamide;
BCNU, carmustine.
†Poor mobilizers, <2  106 CD34+ cells/kg collected. Good mobilizers, ≥2  106 CD34+ cells/kg collected.
‡P value represents comparison between good mobilizers and poor mobilizers.
§Bone marrow involvement refers to involvement by lymphoma at any time before transplantation.
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male patients (P = .01). There was no statistically signiﬁcant
relation to prior radiotherapy exposure or number of differ-
ent types of prior chemotherapy regimens. Although there
was a difference in body mass index (BMI) between male
and female patients (data not shown), we did not ﬁnd any
relation between BMI and ability to mobilize peripheral
cells. Because of the limited records available on the patients
regarding pretransplantation therapies, we were not able to
make a complete evaluation between speciﬁc chemotherapy
exposures and ability to mobilize cells. When multivariate
analysis was performed, female sex was the only factor pre-
dicting poor mobilization (P = .003, odds ratio 4.6).
Hematologic Recovery
Engraftment data are presented in Table 2. There was a
signiﬁcantly shorter time to engraftment of neutrophils and
platelets in good mobilizers, with signiﬁcant P values for all
parameters. When evaluating patients who survived
100 days or more, 9 of 18 (50%) poor mobilizers did not
reach platelet counts exceeding 100,000/µL compared with
4 of 124 (3%) among good mobilizers (P < .0001). There
were no signiﬁcant differences in the proportion of good or
poor mobilizers that received G-CSF beginning on day 1 or
day 6. Patients with <1.0  106 CD34+ cells/kg collected had
signiﬁcantly longer recovery times for neutrophils as well as
platelet counts of 25,000/µL than patients with 1.0  106 to
<2.0  106 CD34+ cells/kg collected (data not shown).
Mortality
Nine patients died of nonrelapse transplantation-related
causes within 120 days of transplantation. Transplantation-
related causes of death include multiorgan failure (n = 3),
aspergillus infections (n = 2), diffuse alveolar hemorrhage (n = 1),
hepatic failure (n = 1), interstitial pneumonitis (n = 1), and gas-
trointestinal bleeding (n = 1). Four poor mobilizers died of
nonrelapse transplantation-related causes within 120 days of
the transplantation (11.8%) compared with 5 patients who
were good mobilizers (3.6%; P = .08). When evaluating deaths
from all causes including relapse within 120 days, there was
also a higher mortality in the poor mobilizers than in good
mobilizers (20.6% [n = 7] versus 8.7% [n = 12], respectively;
P = .06). There was no difference in transplantation-related
mortality when evaluating patients who had mobilized the
lower goal of <1.0 106 CD34+ cells/kg. We attempted to
identify a lower threshold value of CD34+ cells that might
identify a group at highest risk of transplantation-related mor-
tality. Comparisons of the patient group with <1.0 106 CD34+
cells/kg collected and the group with 1.0  106 to <2.0  106
CD34+ cells/kg collected were performed, but no signiﬁcant
differences in transplantation-related mortality could be iden-
tiﬁed, probably because of small patient numbers.
Survival and Relapse
With a median follow-up of 3.5 years (range 19 months
to 5.5 years), 79 patients remain alive and free of disease. A
total of 72 patients have died from all causes. The overall
survival is 54% (95% conﬁdence interval [CI] 45-63%) for
poor mobilizers and 59% (95% CI 55-63%) for good mobi-
lizers (P = .46) (Figure 1). The estimated event-free survival
at 3 years is 48% for patients categorized as good mobilizers
(95% CI 44-52%) versus 45% (95% CI 36-54%) for poor
mobilizers (P = .78) (Figure 2). At a median of 170 days
(range 28-1510 days) after autologous transplantation, 78
patients have relapsed. The Kaplan-Meier estimates of
relapse at 3 years are 44% (95% CI 33-53%) for poor mobi-
lizers and 47% (95% CI 43-51%) for good mobilizers (P =
.59). A higher number of prior chemotherapy regimens was
the only significant predictor of relapse (P = .007), and it
remained signiﬁcant on multivariate analysis (P < .007, haz-
ards ratio = 1.8). There were no differences in survival or
relapse when evaluating extremely poor mobilizing patients
who collected <1.0  106 CD34+ cells/kg.
Cost Analysis
We evaluated a subset of our patients to compare the
cost of transplantation-related care of poor versus good
mobilizers. The subset was chosen based on the availability
of complete cost data for a group of patients with a single
health maintenance organization payer. This group repre-
sented 16 of the poor mobilizers (47%) and 41 of the good
mobilizers (30%). The total cost for bone marrow trans-
plantation–related care was $80,833 for good mobilizers and
$140,264 for poor mobilizers (P = .0001). There was no
signiﬁcant difference in costs for patients with <1.0  106
CD34+ cells/kg collected compared with patients who had
between 1.0  106 and <2.0  106 CD34+ cells/kg collected.
Table 3 demonstrates that many aspects of care for poor
mobilizers were administered at a signiﬁcantly higher cost
because of an increase in use. Both total length of stay and
the length of stay for the transplantation admission were
significantly longer for poor mobilizers, constituting one
contributing cause to the increased cost of care.
DISCUSSION
The data presented in this analysis demonstrate that
patients who mobilize PBPCs poorly can still be considered
suitable candidates for high-dose chemotherapy and autolo-
gous hematopoietic cell transplantation. This is the first
report that describes long-term outcome and cost data for a
group of patients with poor mobilization of PBPCs and who
represent a relatively homogeneous group with a single
diagnosis treated at 1 institution. One report of patients
Table 2. Engraftment Times for Patients Separated by Ability to Mobilize Peripheral Blood Progenitor Cells
Poor Mobilizers* Good Mobilizers* P
Days to absolute neutrophil count >500/µL, median (range) 13 (8-33) 10 (8-27) <.0001
Days to absolute neutrophil count >1000/µL, median (range) 15 (9-39) 10 (8-36) <.0001
Days to platelets >25,000/µL, median (range) 36 (18-68) 14 (8-49) <.0001
Days to platelets >100,000/µL, median (range) 84 (22-84) 23 (11-385) .0006
*Poor mobilizers, <2  106 CD34+ cells/kg collected. Good mobilizers, ≥2  106 CD34+ cells/kg collected.
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with a variety of hematologic malignancies and solid tumors
did demonstrate prolonged hematologic recovery and
increased mortality in patients who mobilized <1  106
CD34+ cells/kg and also had <1  105 granulocyte-mono-
cyte colony-forming cells/kg. We similarly demonstrated a
signiﬁcant transplantation-associated mortality of 11.8% for
poor mobilizers, as well as a 20.6% incidence of early death
from all causes, including relapse. In spite of this increase in
early mortality, with a median follow-up of 3.5 years, the
actuarial event-free and overall survival estimates for this
group are similar to the outcomes for patients who mobi-
lized 2  106 CD34+ cells/kg. In our analysis, no clear PBPC
goal conferred a statistically inferior survival.
In this group of 172 patients, 20% were unable to
mobilize PBPCs sufficiently, defined as a threshold value
of 2  106 CD34+ cells/kg. Although there is no uniform
definition of a poor mobilizer, our previous experience
defined a threshold value of 2  106 CD34+ cells/kg that
predicted prompt hematologic engraftment [20]. Other
investigators reported 8 patients from a group of 60 (13%)
who were unable to mobilize >1  106 CD34+ cells/kg after
CY (3 g/m2) and G-CSF treatment [24]. Similarly, the
group from University College London Hospitals reported
that 15.7% of patients with various malignancies failed to
reach a goal of 1  106 CD34+ cells/kg. The higher inci-
dence of poor mobilizers is probably in part due to a higher
PBPC collection goal in our patient group. The exact num-
ber of apheresis procedures that should be performed in
attempting to collect adequate cells remains unclear. We
performed up to 9 apheresis procedures to reach the PBPC
goal, but in patients who had 3 consecutive poor CD34 col-
lections, the apheresis procedures were stopped and bone
marrow was collected. Although some of our patients might
have met their goal with multiple additional apheresis col-
lections, the quality of such products may be somewhat
questionable.
Poorly mobilizing patients had a significantly higher
cost associated with the transplantation procedure, which in
part might be due to longer length of stay and the need for a
bone marrow harvesting procedure. There was a >50% cost
increase to perform the therapy for poor mobilizers, which
is consistent with other studies that have demonstrated a
Table 3. Costs of Care and Length of Stay for Good and Poor Mobilizers*
Good Mobilizers† Poor Mobilizers† P
Pretransplant costs, $‡ 10,056 25,202 <.001
Transplantation costs, $ 33,643 64,491 .02
Posttransplant costs, $ 23,469 22,494 .61
Professional fees, $ 8316 10,553 .06
Total costs, $ 80,833 140,264 <.001
Length of stay, d
Transplantation 16 24.5 .02
Total 19 30.5 .02
*Cost refers to hospital cost, not patient charges.
†Patients were categorized as “good mobilizers” if a collection of ≥2  106 CD34+ cells/kg was obtained.
‡Includes cost for apheresis and bone marrow harvest, if performed.
Figure 1. Cumulative overall survival for patients mobilizing <2  106 CD34+ cells/kg (3-year estimate: 54%, 95% confidence interval [CI]
45%-63%) (n = 34) ( ) and for patients mobilizing 2  106 CD34+ cells/kg (3-year estimate: 59%, 95% CI 55-63%) (n = 138) ( ); P = .46.
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longer hospitalization and higher cost for patients receiving
a bone marrow graft [35,36]. However, it is important to
note that this group of poor mobilizers is a distinctly differ-
ent population from patients who undergo primary bone
marrow harvest for collection of cells.
Although not the primary goal of this analysis, we iden-
tified both female sex and an increasing number of prior
chemotherapy cycles as signiﬁcant predictors of poor mobi-
lization on univariate analysis. Female sex was the only fac-
tor that remained signiﬁcant in the model on multivariate
analysis (odds ratio 4.6). Many other groups have done more
detailed analyses attempting to predict factors for poor
mobilization, with many groups finding some association
with prior therapies [22,23,37-40].
We have demonstrated no signiﬁcant difference in the
estimated event-free survival, overall survival, or relapse in
patients who mobilized PBPCs poorly after chemotherapy
and G-CSF and received autografting with PBPCs, PBPCs
with ABM, or bone marrow alone. However, our findings
suggest that in a group of patients that may be considered
unfavorable candidates because of decreased stem cell
reserve, autologous transplantation is still a viable treatment
modality. There was also a signiﬁcantly higher cost to per-
form the transplantation procedure in this group of poor
mobilizers. The increased risk of early mortality using
purged autologous marrow is outweighed by the comparable
long-term results of therapy. Patients who fail to mobilize
sufﬁcient PBPCs should be advised of the increased proce-
dure-related risk, but they still may beneﬁt from autologous
transplantation.
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